We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for trametinib (Novartis Pharmaceuticals Australia Pty Ltd)
Active ingredients
trametinib
Date of review outcome
Lapse date
Type
Priority review
Indication
Trametinib, in combination with dabrafenib, is indicated for the adjuvant treatment of patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.
Registration date